Skip to main content

Table 2 Scores of the scales used to evaluate non-motor symptoms of Parkinson’s disease in patients with Gaucher disease type 1 and comorbidities found (n = 23)

From: Evaluation of the frequency of non-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1

Patient BDI ESS UMSARS SST MoCa RBD-1Q MDS-UPDRS III Comorbidities
1 4 6 0 10 30 N 0 Hyperparathyroidism
2 16 11 1 10 26 N 0 Lactating, low vitamin B12 level
3 4 9 0 11 28 N 0 Ulcerative colitis (treated with aminosalicylate), low vitamin B12 level
4 5 8 1 12 29 N 0 None
5 3 17 0 11 23 Y 0 Smoking
6 4 9 1 11 26 N 0 None
7 3 11 1 10 26 N 0 Pulmonary hypertension
8 2 8 1 9 26 Y 0 None
9 12 11 1 12 27 N 0 High blood pressure (treated with angiotensin receptor blockers and diuretics), low vitamin B12 level
10 0 18 0 12 26 Y 0 Smoking
11 6 13 1 12 26 N 0 Asthma, irritable bowel syndrome (treated with antidepressants, spasmolytics, and a beta blocker)
12 7 3 1 12 30 N 0 Smoking; hypertension (treated with beta blocker)
13 2 10 0 10 29 N 0 None
14 4 15 0 12 29 N 0 Cardiomyopathy (treated with beta blockers)
15 25 1 2 10 22 N 0 Smoking, depression (treated with tricyclic antidepressants)
16 33 7 0 11 22 N 0 None
17 6 NP 0 12 26 N 0 Insomnia, anxiety (treated with nonbenzodiazepine hypnotics and selective serotonin reuptake inhibitor), low vitamin B12 level
18 a 14 12 0 6 26 N 0 Hypertension (treated with angiotensin-converting enzyme inhibitors).
19 a 17 4 2 4 22 N 0 Hypertension (treated with calcium channel blockers and beta blocker), osteoporosis, rhinitis
20 13 12 1 10 20 N 27 Hepatocellular carcinoma, hypertension (treated with calcium channel blockers and beta blocker)
21 3 7 0 11 26 N 7 Stroke at age 55; hypertension (treated with calcium channel blockers, angiotensin receptor blockers, and beta blocker)
22 4 13 2 9 19 Y 0 Obesity, osteoporosis, arrhythmia, low vitamin B12 level
23 16 3 1 10 23 N 0 Depression (treated with selective serotonin reuptake inhibitor), hypertension (treated with angiotensin-converting enzyme inhibitor)
  1. Altered results are presented underlined. Bold type denotes patients who screened positive for more than one non-motor symptom of Parkinson’s disease. BDI Beck Depression Inventory (cutoff for depression > 14), ESS Epworth Sleepiness Scale (cutoff for increased daytime sleepiness > 10), UMSARS Unified Multiple System Atrophy Rating Scale (cutoff for constipation ≥2), SST Sniffin’ Sticks Test (cutoff for hyposmia < 9/12), MoCa Montreal Cognitive assessment (cutoff for cognitive impairment < 26), RBD-1Q Single-Question Screen for REM Sleep Behavior Disorder (cutoff being a positive answer to the single question), NP not performed, MDS-UPDRS III motor symptoms of PD assessed with part III of the Unified Parkinson’s Disease Rating Scale. Low vitamin B12 level < 200 pg/mL. aThese patients underwent clinical examination and fiberoptic nasopharyngoscopy by an ENT doctor